ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio Post author:admERY Post published:April 9, 2014 Post category:Newsroom ERYTECH announces the addition of a new product development candidate, erymethionase, to the company’s Cancer Metabolism product pipeline. You Might Also Like ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018 April 12, 2018 ERYTECH to Present at Jefferies Virtual Healthcare Conference November 12, 2020 ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society April 4, 2022
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018 April 12, 2018
ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society April 4, 2022